Cited by 86Metabolism, Diabetes, and CancerBiochemical and Molecular ResearchPeroxisome Proliferator-Activated Receptors

Beyond AICA riboside: In search of new specific AMP‐activated protein kinase activators

Open access
Guigas, Bruno, Sakamoto, Kei, Taleux, Nellie, Reyna, Sara M., Musi, Nicolas, Viollet, Benoit, Hue, Louis·2009·IUBMB Life

Abstract

5‐Aminoimidazole‐4‐carboxamide‐1‐β‐D‐ribofuranoside (AICA riboside) has been extensively used in vitro and in vivo to activate the AMP‐activated protein kinase (AMPK), a metabolic sensor involved in both cellular and whole body energy homeostasis. However, it has been recently highlighted that AICA riboside also exerts AMPK‐independent effects, mainly on AMP‐regulated enzymes and mitochondrial oxidative phosphorylation (OXPHOS), leading to the conclusion that new compounds with reduced off target effects are needed to specifically activate AMPK. Here, we review recent findings on newly discovered AMPK activators, notably on A‐769662, a nonnucleoside compound from the thienopyridone family. We also report that A‐769662 is able to activate AMPK and stimulate glucose uptake in both L6 cells and primary myotubes derived from human satellite cells. In addition, A‐769662 increases AMPK activity and phosphorylation of its main downstream targets in primary cultured rat hepatocytes but, by contrast with AICA riboside, does neither affect mitochondrial OXPHOS nor change cellular AMP:ATP ratio. We conclude that A‐769662 could be one of the new promising chemical agents to activate AMPK with limited AMPK‐independent side effects. © 2008 IUBMB IUBMB Life, 61(1): 18–26, 2009

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/iub.135

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A769662, a non-nucleoside compound thienopyridone, activates AMPK to stimulate glucose uptake in vitro.

    “New promising candidates include A769662, a non-nucleoside compound thienopyridone that activates AMPK to stimulate glucose uptake in vitro 163.”

    From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [163]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Guigas, B., Sakamoto, K., Taleux, N., Reyna, S. M., Musi, N., Viollet, B., & Hue, L.
Affiliations
  • Leiden University Medical Center (NL)
  • University of Dundee (GB)
  • Inserm (FR)
  • Texas Diabetes Institute (US)
  • de Duve Institute (BE)
Corresponding author
Guigas, Bruno
Venue
IUBMB Life
Publisher
Wiley
Published
2008-09-16
Volume
61
Issue
1
Pages
18-26
ISSN
  • 1521-6543 (ISSN-L)
  • 1521-6551
OpenAlex
W1993655397
Cited by
86
References
52
Citations by year
2026: 1 · 2025: 4 · 2024: 2 · 2022: 2 · 2021: 8 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 3 · 2016: 8 · 2015: 5 · 2014: 5 · 2013: 7 · 2012: 4
FWCI
0.64
Type
journal article
Language
en
Open access
Locations
  • IUBMB Life (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • ScholarWorks @ UTRGV (The University of Texas Rio Grande Valley) (submittedVersion)
  • DIAL (Catholic University of Leuven) (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Merck KGaA
  • Diabetes UK (07/0003529)
  • European Commission (LSHMCT-2004-005272)
  • Fonds De La Recherche Scientifique - FNRS
  • National Institutes of Health (07/0003529)
  • Medical Research Council (07/0003529)
  • National Institute on Aging (AG-030979, K23AG030979)
  • National Heart, Lung, and Blood Institute (HL086089, F32HL086089)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK080157, DK-080157)
  • National Institute on Minority Health and Health Disparities (L60 MD000986)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
AMPK, AMPK activators, AICA riboside, A769662, mitochondrial oxidative phosphorylation, AMP/ATP ratio, glucose uptake, myotubes, hepatocytes, energy homeostasis, nucleoside analogues
MeSH terms
Aminoimidazole Carboxamide, Biphenyl Compounds, Glucose, Homeostasis, Humans, Phosphorylation, Pyrones, Ribonucleosides, Thiophenes, Molecular Structure, Enzyme Activators, AMP-Activated Protein Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review